Skip to main content
. 2020 Aug 22;72(10):e526–e532. doi: 10.1093/cid/ciaa1236

Figure 1.

Figure 1.

Susceptibility testing of pentavalent antimony in Leishmania donovani clinical isolates and their recombinants. A, Clinical isolates L. donovani 9515 (▲), 9518 (●), and 9551 (■) were transfected with the firefly luciferase [25] and used to infect THP-1 cells and treated with increasing concentrations of SbV. The average of 4 replicates is shown. All concentration points were statistically significant according to an unpaired t test (2-tailed) at P ≤ .001. B, The luciferase-expressing strains were transfected with a PURO PTR1 inactivation cassette and these parasites were used as controls (black lines for L. donovani 9515 [▲], 9518 [●], and 9551 [■]). The dinucleotide TC indels in AQP1 of 9515 (∆) and 9518 (○) were removed or inserted in 9551 (□) by genome editing, and their susceptibility to SbV is shown with gray lines. All concentration points were statistically significant using an unpaired t test (2-tailed) at P ≤ .001 for 9551(□), P ≤ .01 for 9515 (∆), and P ≤ .001 for 9518 (○). Abbreviations: AQP1, aquaglyceroporin; PTR1, pteridine reductase 1; PURO, puromycin acetyltransferase.